selpercatinib
eli lilly
['libretto-001', 'lcsm,(-blcsm)', 'nsclc', 'sclc']
at #esmo22, we re sharing exploratory posthoc analysis from the libretto-001 trial, assessing safety and efficacy outcomes in a subset of #nsclc pts that continued treatment w/ a selective ret inhibitor beyond disease progression. #lcsm view presentation: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK